汉森制药
(002412)
| 流通市值：35.84亿 | | | 总市值：36.23亿 |
| 流通股本：4.98亿 | | | 总股本：5.03亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 263,228,412.01 | 1,038,756,658.94 | 740,793,882.78 | 508,850,630.33 |
| 营业收入 | 263,228,412.01 | 1,038,756,658.94 | 740,793,882.78 | 508,850,630.33 |
| 二、营业总成本 | 201,768,648.84 | 802,626,275.37 | 573,618,954.13 | 372,994,919.63 |
| 营业成本 | 54,492,826.93 | 235,139,923.3 | 170,079,076.56 | 118,145,490.52 |
| 税金及附加 | 4,902,970.86 | 20,791,077.79 | 14,202,505.85 | 9,302,912.75 |
| 销售费用 | 116,337,931.79 | 430,292,482.29 | 308,377,724.09 | 190,200,177.63 |
| 管理费用 | 17,039,119.05 | 76,642,209.98 | 53,232,365.96 | 36,419,377.62 |
| 研发费用 | 8,961,961.22 | 39,037,413.82 | 27,240,081.51 | 18,508,706.85 |
| 财务费用 | 33,838.99 | 723,168.19 | 487,200.16 | 418,254.26 |
| 其中:利息费用 | 297,333.33 | 1,662,017.79 | 1,340,545.59 | 997,726.24 |
| 其中:利息收入 | 298,182.57 | 1,227,139.06 | 1,006,553.24 | 698,634.38 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 609,206.84 | 1,846,661.4 | 1,394,252.51 | 898,900.83 |
| 加:投资收益 | -10,982,800.43 | 6,348,190.34 | -55,634,757.88 | -39,497,582.73 |
| 资产处置收益 | - | -15,057.11 | 0 | - |
| 资产减值损失(新) | 370,737.95 | -3,140,507.13 | -4,979.71 | 3,834.07 |
| 信用减值损失(新) | -4,510,304.4 | -7,035,307.13 | -2,717,627.46 | -2,668,841.78 |
| 其他收益 | 1,367,973.74 | 5,004,800.8 | 3,332,114.13 | 2,760,638.7 |
| 四、营业利润 | 48,314,576.87 | 239,139,164.74 | 113,543,930.24 | 97,352,659.79 |
| 加:营业外收入 | 111,479.11 | 349,717.9 | 187,470.34 | 136,426.24 |
| 减:营业外支出 | 25,294.12 | 882,426.74 | 616,839.95 | 503,839.35 |
| 五、利润总额 | 48,400,761.86 | 238,606,455.9 | 113,114,560.63 | 96,985,246.68 |
| 减:所得税费用 | 9,994,338.98 | 40,486,007.16 | 30,589,320.44 | 28,446,808.55 |
| 六、净利润 | 38,406,422.88 | 198,120,448.74 | 82,525,240.19 | 68,538,438.13 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 38,406,422.88 | 198,120,448.74 | 82,525,240.19 | 68,538,438.13 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 38,406,422.88 | 198,120,448.74 | 82,525,240.19 | 68,538,438.13 |
| 扣除非经常损益后的净利润 | 36,085,207.02 | 189,879,128.19 | 77,138,034.56 | 64,769,529.97 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.08 | 0.39 | 0.16 | 0.14 |
| (二)稀释每股收益 | 0.08 | 0.39 | 0.16 | 0.14 |
| 八、其他综合收益 | 3,597,870.66 | -20,578,904.05 | -25,082,136.89 | -16,205,404.86 |
| 归属于母公司股东的其他综合收益 | 3,597,870.66 | -20,578,904.05 | -25,082,136.89 | -16,205,404.86 |
| 九、综合收益总额 | 42,004,293.54 | 177,541,544.69 | 57,443,103.3 | 52,333,033.27 |
| 归属于母公司股东的综合收益总额 | 42,004,293.54 | 177,541,544.69 | 57,443,103.3 | 52,333,033.27 |
| 公告日期 | 2026-04-28 | 2026-04-28 | 2025-10-28 | 2025-08-26 |
| 审计意见(境内) | | 标准无保留意见 | | |